Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingSierra Health and Life Molecular Oncology Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentsierra health and lifePolicy 2026T0588QQ

    Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026T0588QQ alerts

    Get alerted when Policy 2026T0588QQ changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage of molecular oncology testing for diagnosis, prognosis, and treatment decisions for solid tumor cancers under Sierra Health and Life (UnitedHealthcare) Commercial and Individual Exchange benefit plans. Applies to tests that are not FDA-cleared/approved companion diagnostics.

    Policy Summary
    Payersierra health and life
    PolicyMolecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions
    Policy CodePolicy 2026T0588QQ
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionWhen ordering non–FDA-cleared molecular oncology tests, document clinical indication and how results will affect management to support coverage review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplecovered tumor types
    50+named unproven tests
    83%Shield sensitivity
    91%MammaPrint concordance
    ~70+coding items listed

    Coverage Criteria and Evidence Summaries

    Breast Cancer — GEP (initial)

    Breast cancer—Gene expression profiling tests proven and medically necessary when ALL of the following are met

    Breast GEP initial: Newly diagnosed within the last 6 months; lymph node negative (including micrometastases ≤2 mm) OR 1–3 positive ipsilateral axillary lymph nodes; no distant metastases; hormone receptor–positive (ER and/or PR); HER2–negative; adjuvant chemotherapy is not precluded by other factors (e.g., advanced age or significant comorbidities)

    Applies to MammaPrint, Oncotype DX Breast Recurrence Score, Prosigna, Breast Cancer Index, EndoPredict

    Breast GEP extended therapy: Currently receiving adjuvant hormonal therapy (e.g., tamoxifen or aromatase inhibitor); hormone receptor–positive; HER2–negative; treating physician and patient discussed potential test results prior to testing and intend to use results to guide decision on extended adjuvant hormonal therapy

    Applies to listed GEP tests; BCI may be used specifically to inform extended endocrine therapy decisions

    Breast Cancer — GEP (extended therapy)

    Breast cancer—GEP for extended endocrine therapy decision when ALL of the following are met

    Policy Summary
    Payersierra health and life
    PolicyMolecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions
    Policy CodePolicy 2026T0588QQ
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionWhen ordering non–FDA-cleared molecular oncology tests, document clinical indication and how results will affect management to support coverage review.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummariesCovered Indications — Specific Tests and Clinical ContextsEligibility Requirements and Operational NotesProvider Actions, Prior Authorization, and DocumentationApplicable Procedure and Test CodesNot Covered / Unproven TestsBackground and ScopeDefinitionsAdditional Provider Actionables and Documentation RequirementsRevision History
    Breast GEP extended therapy: Currently receiving adjuvant hormonal therapy (e.g., tamoxifen or an aromatase inhibitor); hormone receptor–positive; HER2–negative; individual and treating physician have discussed potential results and will use results to guide decision on extended adjuvant hormonal therapy

    Applies to specific GEP tests as listed (e.g., Breast Cancer Index)

    Colorectal Cancer — Shield

    Colorectal cancer — Shield blood-based screening is proven and medically necessary when ALL of the following are met

    Shield CRC screening: Individual agrees to undergo follow-up colonoscopy if Shield results are abnormal; no lower gastrointestinal pain, rectal bleeding, or other signs/symptoms suggestive of colorectal disease; average risk for CRC (no personal history of adenomatous polyps, CRC, inflammatory bowel disease, and no first-degree relative with CRC, adenomatous polyps, familial adenomatous polyposis, or Lynch syndrome); and age 45–75 with no recent guideline-recommended screening OR age 76–85 meeting additional criteria (never screened, healthy enough for treatment if CRC detected, no comorbid conditions limiting life expectancy)age 45–75 (or 76–85 with conditions)

    Positive Shield test requires diagnostic colonoscopy follow-up; screening intervals per policy (Shield every 3 years) are specified

    Lung Cancer — NSCLC panels

    Lung cancer — multigene profiling panels

    NSCLC panels: Multigene molecular profiling panels used for non–small cell lung cancer are medically necessary when the panel includes no more than 50 genes; broad panel testing (often >50 genes) is recommended by guidelines when feasible, but the Medicare-specific necessity statement limits covered panels to ≤50 genes≤50 genes

    Plasma ctDNA testing may be used in advanced/metastatic disease or when tissue is insufficient (see guidelines); ctDNA should not replace tissue when tissue is available

    Prostate Cancer — Genomic testing

    Prostate cancer — genomic tests for localized, untreated disease and post-prostatectomy decision-making

    Genomic Prostate Score/Prolaris/Decipher biopsy: Biopsy-proven, untreated, localized adenocarcinoma of the prostate with no clinical metastasis; test ordered by a physician specializing in organ-confined prostate cancer (urology, radiation oncology, medical oncology); results intended to assist treatment decision-making for candidates for active surveillance or definitive therapy; life expectancy >10 years; risk group within specified categories (very low, low, favorable intermediate, etc., per NCCN definitions)

    Applies to Genomic Prostate Score (GPS), Prolaris Biopsy, Decipher Prostate Biopsy

    Decipher RP post-prostatectomy: Decipher Prostate RP genomic classifier is proven and medically necessary to inform adjuvant treatment after radical prostatectomy when adverse features are present (e.g., Gleason ≥8, extracapsular extension, positive margins, seminal vesicle invasion) OR when PSA is >0 after prostatectomy

    Applies to Decipher Prostate RP indication

    Anaplastic Thyroid Cancer — CGP

    Anaplastic thyroid cancer

    Anaplastic thyroid CGP: Comprehensive genomic profiling of confirmed anaplastic thyroid carcinoma is proven and medically necessary to identify actionable alterations and inform systemic/targeted therapy decisions

    Includes testing for mutations/fusions per guideline recommendations (e.g., BRAF, NTRK, RET, ALK, MSI/dMMR, TMB)

    Thyroid Nodules — Molecular testing

    Indeterminate thyroid nodules

    Thyroid nodule molecular testing: Fine-needle aspiration cytology demonstrates indeterminate follicular-pattern pathology (Bethesda III or IV); and the molecular test result will be used to guide a decision about further surgery (avoid or proceed to diagnostic/definitive thyroidectomy)Bethesda III/IV

    Examples include Afirma GSC, ThyroSeq V3, ThyGeNEXT/ThyraMIR; use of more than one molecular test on the same nodule is unproven and not medically necessary

    Uveal Melanoma — GEP

    Uveal melanoma

    Uveal melanoma GEP: Primary, localized uveal melanoma with no evidence of metastatic disease; the individual has not previously had DecisionDx-UM testing for the current diagnosis; results will be used to inform prognostic counseling, surveillance intensity, or clinical trial eligibility

    Applies to DecisionDx-UM 15-GEP and may be combined with PRAME expression testing for refined stratification

    Unproven Molecular Tests

    Unproven molecular tests designated in the policy

    Unproven tests listed: Specific tests explicitly identified as 'Unproven Molecular Tests' in the policy and considered not medically necessary pending sufficient evidence, including but not limited to Tempus Immune Profile Score, whole-genome methylation profiling, and EpiSwitch Checkpoint inhibitor Response Test.

    Tests listed as unproven are subject to noncoverage per policy

    Clinical evidence and scope statements

    Context and evidence summaries relevant to coverage decisions

    evidence_summary: Gene expression profiling tests (Oncotype DX, MammaPrint, Prosigna, EndoPredict, BCI) are prognostic for distant recurrence in HR-positive, HER2-negative early breast cancer; predictive evidence for chemotherapy benefit is strongest for Oncotype DX, with menopausal status modifying observed benefit

    Derived from systematic reviews and randomized trials cited in the policy

    evidence_limits: Predictive data are limited for Prosigna and EndoPredict in node-positive disease; MINDACT and other trials had subgroup limitations; decision-impact evidence is concentrated for Oncotype DX

    These limitations affect interpretation of predictive utility in certain populations

    multigene_definition: For this policy, multigene analysis generally refers to a gene panel containing five or more genes; panel size and intended clinical use influence coverage assessment>=5 genes generally

    Coding lists and policy definitions provide operational guidance

    Evidence-supported clinical applications

    Clinical scenarios supported by evidence in the provided excerpts:

    Oncotype DX - node-negative HR+ HER2-: Oncotype DX 21-gene recurrence score is prognostic for distant recurrence and can inform adjuvant chemotherapy decisions in early HR-positive, HER2-negative, node-negative breast cancer (TAILORx and meta-analyses); integrating RS with clinicopathologic factors improves prognosticationRS categories referenced in trials

    Strongest predictive evidence among GEPs

    Oncotype DX - node-positive (N1): In selected patients with 1–3 positive nodes, Oncotype DX may provide prognostic information and influence chemotherapy decisions; RCT data (e.g., RxPONDER) show differential benefit by menopausal statusN1 (1–3 positive nodes)

    Evidence for predictive benefit is concentrated for Oncotype DX

    Prosigna (PAM50): Prosigna ROR identifies subgroups with very low long-term local recurrence after breast-conserving surgery and endocrine therapy in postmenopausal ER+ patients but lacks evidence of predicting radiotherapy benefitROR cutoffs used in studies

    Prognostic for local recurrence; predictive value for RT not demonstrated

    MammaPrint/BluePrint: MammaPrint and BluePrint findings from neoadjuvant trials (I-SPY2) associate molecular subgroups with pathological complete response and DRFS in selected high-risk HR+ patients; prospective validation required for routine useMP risk classifications

    Adaptive trial data are promising but not definitive

    Evidence summaries informing coverage

    Summary of clinical evidence relevant to coverage decisions:

    EndoPredict evidence: EndoPredict EPclin stratifies relapse risk in ER+, HER2- early breast cancer with reported low vs high relapse rates at 60 months in cohort studies; limitations include enrichment for higher-risk participants, limited prospective validation, and limited applicability across premenopausal patients

    Prospective and retrospective studies cited (Penault-Llorca, Dubsky, Sestak); Hayes assessment notes additional evidence gaps

    BCI evidence: Breast Cancer Index is prognostic for distant recurrence and in multiple studies influenced extended endocrine therapy recommendations and patient/provider decisions, though predictive evidence varies by cohort and some reviews cite limited prospective data

    Sanft registry and prospective-retrospective analyses support decision impact but further validation recommended

    ctDNA prognostic evidence: Baseline ctDNA detection in metastatic breast cancer is associated with worse survival (pooled HR ~1.40) and is prognostic across studies, though current evidence frames ctDNA as prognostic rather than definitively actionable for therapy selection in many contexts

    Dickinson et al. systematic review and meta-analysis

    DCIS genomic assays: Genomic assays for DCIS (DCISionRT, Oncotype DX DCIS score) show potential to risk-stratify local recurrence but evidence is largely retrospective and insufficient to confirm impact on long-term outcomes

    Systematic reviews (Chen et al.) highlight limited prospective outcome data

    Clinical contexts where testing is discussed or recommended

    Use of genomic assays or broad molecular profiling supported or recommended in the following clinical contexts per cited guidelines and evidence summaries:

    Breast cancer - GEAs for adjuvant therapy decisions: Guidelines (ASCO, ESMO, NICE, NCCN) support use of Oncotype DX, MammaPrint, BCI, and EndoPredict in defined early-stage ER+/HER2- populations (node-negative or 1–3 positive nodes) with menopausal/age distinctions; BCI may aid extended endocrine therapy decisions after 5 years of ETnode-negative or 1–3 positive nodes; menopausal status considered

    Guideline specifics inform appropriate testing populations

    Lung cancer - broad molecular testing: ASCO and NCCN recommend broad panel NGS for NSCLC to identify actionable alterations; plasma ctDNA testing is an option in advanced/metastatic disease or when tissue is insufficient, with tissue follow-up if ctDNA is negative for a driverpanel-based NGS often >50 genes (guideline note)

    Supports broad molecular profiling for treatment selection

    Thyroid nodules - molecular testing: ATA, AAES, and NCCN recommend selective use of molecular testing for indeterminate cytology (Bethesda III/IV) to supplement malignancy risk assessment and to inform decisions about surgery when results would change managementBethesda III/IV

    Counseling on benefits/limitations and consideration of institutional malignancy rates recommended

    Decipher GC — prognostic and potential predictive utility

    Decipher genomic classifier — evidence-based considerations

    Decipher prognostic evidence: Multiple randomized trial ancillary analyses, prospective and retrospective cohorts, and large registry linkages show Decipher GC is independently prognostic for biochemical failure, metastasis, and prostate cancer–specific mortality; utility strongest in intermediate-risk disease and post-prostatectomy settings

    Supported by NRG/RTOG ancillary analyses and large real-world cohorts (Spratt, Leapman, Jairath reviews)

    Predictive/utility signals: Analyses such as PORTOS and ancillary trial data suggest Decipher-derived signals may predict benefit for treatment intensification (e.g., radiation dose escalation) in select contexts, but prospective outcome-improvement evidence is limited

    Predictive signals exist but require further prospective validation

    Liquid biopsy and urine-based biomarker assays

    Urine and exosome liquid biopsy tests — diagnostic and utility evidence

    ExoDx Prostate: Prospective randomized utility trial and systematic reviews show ExoDx Prostate influences biopsy decisions and improves detection of high-grade prostate cancer compared with PSA alone in men with PSA commonly studied between 2 and 10 ng/mL; overall evidence quality varies and further prospective data recommendedPSA 2–10 ng/mL commonly studied

    Tutrone RCT and systematic reviews cited

    Other urine/liquid assays: Tests such as MyProstateScore, Select mdx, Confirm mdx show heterogeneous performance and limited prospective validation; evidence insufficient for routine broad implementation outside studied populations

    Meta-analyses and Hayes assessments identify evidence gaps

    Covered uses when results would affect management

    Covered when testing is expected to influence clinical management and aligns with guideline recommendations:

    Thyroid nodule molecular testing: Molecular testing (e.g., Afirma GSC, ThyroSeq V3, ThyGeNEXT/ThyraMIR) may be considered for nodules with indeterminate cytology (Bethesda III/IV) when results would change management (avoid vs proceed to surgery) and after documenting clinical, sonographic features and informed patient preferenceBethesda III/IV

    Guidelines emphasize counseling and consideration of institutional malignancy rates

    Anaplastic/unresectable thyroid cancer: For anaplastic thyroid carcinoma or RAI–resistant differentiated thyroid cancer, tumor-based molecular testing to identify actionable driver alterations (e.g., BRAF, NTRK, ALK, RET, MSI/dMMR, TMB) is recommended when results will inform systemic therapy

    NCCN recommends testing for specified actionable alterations

    Melanoma SLNB decision support: GEP tests (31-GEP, CP-GEP/Merlin) may be considered to aid SLNB decision-making in T1–T3 cutaneous melanoma when test performance achieves acceptably low false omission rates and results will directly influence managementfalse omission rate target per guideline considerations

    31-GEP studies reported favorable false omission rates; CP-GEP results more variable

    Evidence-linked coverage considerations

    Coverage considerations based on available evidence and intended clinical use:

    CP-GEP (Merlin) evidence for SLNB: CP-GEP may inform SLNB decision-making for biopsy-proven T1–T3 cutaneous melanoma with clinically negative regional nodes; prospective multicenter data reported NPV of 92.9% and 7.1% SLN positivity among CP-GEP low-risk cases, indicating potential utility but need for further high-quality prospective validationNPV ~92.9% reported

    Hieken prospective study (n=1,761) cited; limitations include selection and enrollment criteria

    31-GEP evidence for SLNB decisions: 31-GEP results influenced clinician decisions and were associated with reductions in SLNB rates in prospective studies (e.g., 29.4% reduction for class 1A in DECIDE), and stratified 5-year survival across classes; evidence limited by study designs and lack of randomized trials demonstrating outcome improvement

    DECIDE and other prospective/observational studies cited

    DecisionDx-UM evidence: DecisionDx-UM GEP and PRAME expression reliably stratify metastatic risk in uveal melanoma cohorts with large prognostic separation (5-year MFS 92.3% vs 52.1% for class 1 vs class 2) and support informing surveillance intensity and trial stratification, though RCT outcome benefits are not established

    Harbour multicenter prospective cohort (n=1,577) provides principal evidence

    Evidence-informed coverage considerations

    Evidence and guideline-informed considerations from the document:

    Uveal melanoma prognostic testing: DecisionDx-UM and PRAME expression stratify metastatic risk and may influence surveillance and referral decisions; Hayes assessment notes low-quality evidence overall but consistent prognostic signal

    Harbour et al. and Hayes assessments cited

    Guideline cautions for cutaneous melanoma GEP: Major guidelines (NCCN, SSO, AAD) generally discourage routine prognostic GEP testing for cutaneous melanoma outside research and do not recommend replacing SLNB or established staging with GEP for prognostication

    NCCN and SSO recommendations referenced

    Bladder urine assays evidence: Cxbladder Triage and Bladder EpiCheck show high NPV and may reduce unnecessary cystoscopies in selected lower-risk populations; both tests are adjuncts and do not replace cystoscopy in higher-risk patientsEpiScore >=60 positive threshold reported for methylation assays

    AUA and NCCN guidance reference UBTMs as options in specific scenarios

    Bladder EpiCheck

    Bladder EpiCheck — evidence summary and inferred coverage considerations

    EpiCheck evidence: Prospective multicenter and pooled analyses report pooled sensitivity ~82%, high-grade sensitivity ~91%, specificity ~85%, and high-grade NPV up to 98%; EpiScore cutoffs (≥60, ≥80) correlate with recurrence risk in cohort studiesEpiScore >= 60 (positive)

    Fleshner prospective cohort and meta-analyses cited; randomized trials lacking

    Cxbladder Triage / Monitor

    Cxbladder — evidence summary and inferred coverage considerations

    Cxbladder Triage RCT evidence: A multicenter randomized trial in lower-risk microhematuria showed a 59% relative reduction in cystoscopy rates using Cxbladder Triage without compromising detection; reported sensitivity 90% and NPV 99% in trial lower-risk participants, supporting use to reduce unnecessary cystoscopy in appropriately selected lower-risk patientsLower-risk microhematuria strata per trial definitions

    AUA guidance allows UBTMs for appropriately counseled intermediate-risk patients who accept avoiding cystoscopy

    Decipher Bladder

    Decipher Bladder genomic classifier — evidence summary and inferred coverage considerations

    Decipher Bladder evidence: Retrospective multicenter studies show Decipher Bladder subtyping (luminal vs nonluminal) associates with pathological upstaging and overall survival differences; nonluminal tumors have higher upstaging and worse OS and may derive greater benefit from neoadjuvant chemotherapy in pooled analysesmolecular subtype (luminal vs nonluminal)

    Evidence largely retrospective; prospective validation needed

    DecisionDx-SCC (40-GEP)

    DecisionDx-SCC (cSCC) — evidence summary and inferred coverage considerations

    DecisionDx-SCC evidence: Retrospective validations and multidisciplinary consensus suggest DecisionDx-SCC (40-GEP) stratifies metastatic risk (class 1, 2A, 2B) and may identify patients likely to benefit from adjuvant radiotherapy (class 2B associated with largest ART benefit); overall evidence quality is low and manufacturer involvement notedGEP class categories (class 1, 2A, 2B)

    Hayes assessment and retrospective multicenter studies cited; prospective utility data limited

    Clinical evidence-based coverage considerations

    Clinical evidence-based coverage considerations

    cSCC decision considerations: DecisionDx-SCC may improve prognostic stratification beyond clinicopathologic systems but prospective utility to improve outcomes is unproven; guideline bodies (SITC) caution against predictive use for ICI benefit

    Retrospective multicenter validations and consensus reports referenced

    CUP and CGP: Comprehensive genomic profiling in unfavorable CUP improved progression-free survival in CUPISCO, especially for patients with actionable alterations; documentation of actionable findings and intended targeted therapy is important for coverage considerationmedian PFS improvement reported (6.1 vs 4.4 months)

    CUPISCO randomized data support CGP in unfavorable CUP

    GEP for tissue-of-origin: GEP tests for tissue-of-origin (e.g., CancerTYPE ID) have limited evidence for improving outcomes in CUP; DNA sequencing may provide added diagnostic value in many cases

    Systematic reviews and prospective studies (SUPER) cited

    Shield blood-based CRC screening: Guardant Shield cfDNA blood-based screening has FDA approval and demonstrated sensitivity ~83.1% for CRC and specificity ~89.6% for advanced neoplasia in ECLIPSE; positive results require diagnostic colonoscopysensitivity 83.1%; specificity 89.6%

    ECLIPSE prospective study cited; limited sensitivity for advanced precancerous lesions

    General evidence heterogeneity: Overall evidence across molecular oncology tests is heterogeneous: some assays have randomized/prospective data supporting clinical utility in narrow contexts, whereas many GEPs, CGP panels, and multicancer detection assays lack high-quality outcome data; coverage decisions should reflect test-, tumor-, and indication-specific evidence and guideline positions

    Policy emphasizes tumor-specific evidence and guideline alignment

    This policy applies to molecular oncology tests for solid tumors that are not FDA-cleared or -approved as companion diagnostics. Tests that meet the FDA companion diagnostic designation fall outside the scope of this policy and should be evaluated under the separate FDA Cleared or Approved Companion Diagnostic Testing policy. Tests identified in the policy as “Unproven Molecular Tests” are considered not supported by sufficient evidence and are subject to noncoverage or denial consistent with the policy position on unproven testing.

    For reference and adjudication purposes the policy lists examples of tests designated as “Unproven Molecular Tests.” Examples include, but are not limited to: Tempus Immune Profile Score, whole-genome methylation profiling, EpiSwitch Checkpoint Inhibitor Response Test, CancerTYPE ID, Bladder EpiCheck, Cxbladder Triage/Monitor, Decipher Bladder Genomic Classifier, DecisionDx-Melanoma, DecisionDx-SCC (40-GEP), DermTech PLA, Merlin, MyPath Melanoma, Confirm mdx, ExoDx Prostate, MyProstateScore 2.0, Select mdx, Guardant Reveal, Signatera, Galleri, and other named assays enumerated in the Unproven Molecular Tests list.

    Cancer screening tests that are covered under a member’s preventive care benefit are addressed separately in the plan’s Preventive Care Services policy. Where a molecular oncology assay is intended for routine population screening and that indication is included in the Preventive Care Services policy, follow that policy for coverage determination rather than this molecular oncology testing policy.

    Evidence limitations create gaps in applicability of some gene expression assays (GEAs) across patient subpopulations. Several GEAs have strong prognostic data overall but remain unvalidated or of uncertain predictive value in defined subgroups (for example, by menopausal status or nodal category). Published analyses and assessments note limited prospective data, enrichment for higher-risk trial cohorts, and insufficient follow-up for late recurrences that constrain generalizability of findings to all patient populations.

    Key study limitations cited across several GEA evaluations include cohort enrichment for higher-risk participants, frequent concomitant chemotherapy use that complicates assessment of assay-predicted treatment benefit, and relatively short or incomplete follow-up for detection of late distant recurrences. These design limitations and potential sponsor conflicts of interest were repeatedly noted as reasons why prospective, randomized validation is still needed for certain clinical claims.

    Gene expression profiling assays developed for ductal carcinoma in situ (DCIS) and other breast cancer assays beyond the principal, well-studied GEAs currently lack sufficient evidence of clinical utility. Specifically, assessments (Hayes and other systematic reviews) conclude that DCISionRT and the Oncotype DX Breast DCIS Score have low-quality or insufficient evidence to support routine clinical implementation for guiding radiotherapy or other definitive management decisions.

    Clinical guideline panels do not recommend use of GEAs to guide management in patients with HER2-positive or triple-negative breast cancer; GEAs are primarily relevant to prognostication and adjuvant systemic therapy selection in hormone receptor–positive, HER2-negative disease. NCCN specifically notes GEAs are not required for staging and does not recommend them for HER2+ or TNBC populations.

    Plasma circulating tumor DNA (ctDNA) testing has a defined role in the advanced/metastatic setting or when tissue biopsy is unsafe or insufficient. The NCCN and the policy make clear that ctDNA should not be used in lieu of a tissue diagnosis in non‑metastatic disease; when ctDNA is performed because tissue is unavailable, plans should document the clinical rationale and pursue tissue testing or follow-up as clinically indicated if no actionable driver is identified on plasma testing.

    Several commercially marketed assays for prostate cancer detection or risk stratification (for example, MyProstateScore 2.0, OncoAssure, Confirm mdx) have been judged to lack sufficient peer‑reviewed evidence of clinical validity or utility. Hayes assessments and other evidence reviews concluded that current data are inadequate to support routine clinical use of these tests outside specified evidence‑based indications.

    In prostate cancer evaluation, guideline panels (NCCN) state biomarker tests should not replace a multiparametric MRI when MRI is available and of adequate quality. Biomarker testing may be considered in select circumstances when MRI is unavailable, contraindicated, or of low quality, but should not be used as a routine substitute for mpMRI.

    Molecular testing is not recommended routinely to guide postoperative radioiodine therapy in differentiated thyroid cancer. For indeterminate thyroid cytology and unresectable or anaplastic thyroid cancers, molecular testing may inform management, but routine molecular testing to determine postoperative radioiodine decisions lacks supporting outcome evidence.

    Tests supported only by low- or very-low–quality evidence, such as MyPath Melanoma per Hayes assessment, are not supported for routine clinical use as diagnostic adjuncts because available studies are insufficient to demonstrate improved patient outcomes.

    Predictive gene expression profiling should not replace surgical or pathological staging discussions (for example, sentinel lymph node biopsy) in routine practice. Major guideline statements caution against using GEPs as a substitute for established surgical staging procedures outside of clinical trials; molecular test results may be used as adjunctive information but should not be the sole basis to forego recommended staging procedures.

    Across many test evaluations, the evidence base is limited by retrospective or single‑center study designs, potential selection bias, and frequent conflicts of interest or manufacturer sponsorship. The policy notes these limitations and highlights the need for larger, multicenter prospective trials with independent assessment to establish clinical utility and generalizability.

    Assays intended to infer the primary site in cancers of unknown primary (for example, gene expression classifiers such as CancerTYPE ID) currently lack sufficient peer‑reviewed evidence demonstrating improved clinical outcomes or reliable clinical effectiveness for guiding site‑specific therapy, and therefore are considered unsupported for routine clinical use pending higher‑quality validation.

    The policy’s default position is that molecular oncology tests for solid tumors that are not specifically listed as proven and medically necessary in this document are considered unproven and therefore not medically necessary. Tests named in the Unproven Molecular Tests list should be treated as lacking coverage support unless later evidence or policy revision documents a proven indication.

    Named tests included in the Unproven Molecular Tests lists are examples of assays that the policy implies are currently without coverage support pending stronger evidence of clinical validity and demonstrable clinical utility. Providers should assume these named assays are not supported for routine coverage unless an applicable medical necessity criterion elsewhere in the policy or a separate FDA companion-diagnostic designation applies.

    Some chunks summarize evidence without making explicit ‘‘not medically necessary’’ statements; the document emphasizes uncertainty in predictive utility for many assays except for Oncotype DX, which has the strongest predictive data for chemotherapy benefit among the breast GEAs assessed. Policy language and evidence summaries should be interpreted with that context in mind.

    Hayes assessments highlighted limitations for Oncotype DX in certain settings, for example the lack of sufficient evidence to support its use to estimate distant recurrence risk and chemotherapy benefit in patients with N2 disease (four to nine positive lymph nodes). These assessments inform restricted use in more heavily node‑positive populations.

    Hayes assessments for EndoPredict and Breast Cancer Index (BCI) concluded that although each assay demonstrates prognostic signal for distant recurrence, evidence is insufficient to reliably predict benefit of extended endocrine therapy or to estimate long-term distant recurrence risk in all patient subgroups without further prospective validation. The policy therefore treats certain predictive indications for these assays as uncertain pending higher‑quality data.

    Hayes reviews concluded there is inadequate or low‑quality evidence to support routine clinical use of DCISionRT and that the evidence supporting the Oncotype DX DCIS score is low quality; outcome data demonstrating benefit from score‑directed management are lacking, and the Hayes updates indicate current ratings are unlikely to change absent new high‑quality studies.

    Covered Indications — Specific Tests and Clinical Contexts

    Eligibility Requirements and Operational Notes

    No top-level eligibility nodes are specified in the extracted eligibility chunks. Where eligibility criteria are defined elsewhere in the policy (for example, age limits for CRC screening with Shield or clinical scenario requirements for breast GEPs), those specific criteria govern coverage decisions.

    This block is a placeholder. The policy’s eligibility sections contain specific, test- and indication-based requirements elsewhere (e.g., age and risk criteria for Shield CRC screening; clinical criteria for breast GEPs).

    Fallback placeholder: where the inventory contains no explicit eligibility nodes for a given subsection, providers should rely on the test-specific coverage criteria and the member’s benefit document when determining coverage eligibility.

    Test-specific eligibility placeholder for thyroid nodules: molecular testing is considered when fine-needle aspiration cytology is indeterminate (Bethesda III/IV) and the test result will be used to inform the decision about further surgery.

    This block is a placeholder where no top-level eligibility nodes are present in the inventory excerpt; consult the policy text for detailed, indication-specific eligibility criteria.

    Placeholder: when eligibility is not specified in a subsection, clinical documentation supporting intended use and concordance with policy-listed indications will be required for consideration.

    Placeholder: multigene analysis is generally defined as a panel of five or more genes, and documentation should demonstrate that the assay meets the policy’s intended-use population and analytic scope.

    Placeholder: for ctDNA tests used when tissue is unavailable, documentation should describe why tissue biopsy was not feasible and how ctDNA results will influence management.

    Placeholder: where timing thresholds apply (for example, some breast GEPs are intended for newly diagnosed patients), providers should document recency of diagnosis per the policy criteria.

    Placeholder: eligibility confirmation should reference the detailed clinical criteria in the policy sections associated with each covered test and indication.

    Placeholder: when more than one molecular test is considered for a single thyroid nodule, the policy notes that performing multiple tests is unproven and not medically necessary.

    Placeholder: where the inventory is empty for an eligibility subsection, standard documentation and justification aligning with the policy’s definitions and covered indications are expected.

    Placeholder: providers should attach clinical notes showing how test results would influence management when eligibility is not explicitly enumerated for a given assay in the inventory excerpt.

    Placeholder: where no explicit eligibility nodes exist, clinical justification consistent with guideline-supported indications should be provided for review.

    Placeholder: documentation of the multigene panel composition (number of genes, gene classes evaluated) may be requested when eligibility is uncertain.

    Placeholder: if an assay or indication is not listed, the test will be evaluated against the policy’s evidence framework and definitions for multigene analyses and intended clinical use.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization applies to non‑FDA companion diagnostics

    This policy applies to molecular oncology tests that are not FDA‑cleared or FDA‑approved companion diagnostics; prior authorization and coverage determinations for such tests should follow the terms of this medical policy and associated coding pages.

    Note

    Codes are reference‑only — inclusion does not equal coverage

    The procedure and diagnosis code lists in this policy are provided for reference only; listing a code does not imply the service is covered or payable and payers should verify member benefits and other applicable policies prior to assuming coverage.

    Prior Authorization

    Prior auth may be required for listed molecular oncology codes

    Prior authorization may be required for molecular oncology multigene panels and for unlisted molecular pathology procedures identified in the policy (e.g., CPT/PLA panels and unlisted molecular pathology codes).

    • Examples of listed CPT/PLA codes include multigene genomic panel codes (e.g., 81445, 81456, 81462) and unlisted molecular pathology code 81479.
    Documentation Required

    Document rationale when plasma ctDNA used due to insufficient/unsafe tissue

    If ordering plasma ctDNA because tissue is inadequate or biopsy is unsafe, document the clinical circumstances (e.g., inability to obtain tissue, medical contraindication to biopsy) and plans to pursue tissue testing if ctDNA is non‑informative.

    • NCCN: ctDNA may be used when patient medically unfit for invasive sampling or tissue insufficient; ctDNA should be followed by tissue‑based analysis when no oncogenic driver is identified.
    Prior Authorization

    Prior auth likely requires clinical indication and PSA range for prostate assays

    For prostate genomic/urine assays (e.g., ExoDx, Select mdx) prior authorization requests may need documentation of the clinical indication and the PSA range studied (commonly 2–10 ng/mL for ExoDx) to support use for biopsy decision support.

    • ExoDx is studied in men with PSA 2–10 ng/mL and evidence for clinical utility is limited — document indication and PSA value.
    Prior Authorization

    Prior authorization for guideline‑listed molecular tests should document intended guideline use

    When tests are ordered that are listed as guideline options (for example Decipher, ExoDx, Afirma, ThyroSeq), prior authorization reviewers may require documentation showing the test is being used in a guideline‑recommended clinical context and how results will influence management.

    • Provide guideline alignment (which guideline and recommendation) and intended clinical use in the authorization request.
    Prior Authorization

    Authorization should document guideline‑indicated clinical rationale and tissue availability

    Prior authorization approvals should align with guideline‑indicated uses (e.g., reclassifying follicular lesions or identifying actionable mutations in unresectable/anaplastic thyroid cancer); include clinical and imaging findings and rationale for testing.

    • Document that testing will inform a treatment decision consistent with guideline recommendations (ATA/NCCN/AAES).
    Prior Authorization

    If test will guide SLNB, submit staging and management impact documentation

    When molecular GEP results are intended to change sentinel lymph node biopsy (SLNB) management, prior authorization may require submission of tumor staging, T category, and documentation that the assay result will impact the SLNB decision.

    • Include tumor T category/stage and a statement of how a low‑risk or high‑risk GEP result will alter SLNB management.
    Prior Authorization

    Document that results will inform treatment or trial eligibility for authorization

    If testing will be used to determine treatment selection or clinical trial eligibility, prior authorization should document that results are expected to inform a specific therapy or trial entry and include the planned therapeutic decision pathway.

    • For CGP in CUP, show how identified actionable findings would change therapy selection or trial eligibility.
    Prior Authorization

    Provide guideline‑based justification for urine/tissue molecular tests

    For molecular urine or tissue assays, provide guideline‑based justification in prior authorization requests showing how the test aligns with guideline roles (e.g., AUA/NCCN statements on UBTMs) and the intended management change.

    • Reference the guideline recommendation and explain how a positive or negative test will change clinical follow‑up or procedures.
    Prior Authorization

    For CGP‑directed CUP therapy, document tissue status and actionable findings plan

    When CGP is requested to guide therapy in cancers of unknown primary (CUP), prior authorization may require documentation of tissue availability, prior induction therapy (if applicable), and evidence that identified actionable findings will be used to select targeted therapy.

    • Include whether tissue was available, CGP results or expected targets, and plan for molecular tumor board review if applicable.
    Step Therapy

    Step/entry criteria required for select breast and thyroid tests

    Certain breast and thyroid molecular tests require specific clinical criteria before testing (e.g., breast GEP timing relative to diagnosis or ongoing adjuvant hormonal therapy; thyroid tests applied to Bethesda III/IV nodules). Ensure prior authorization or ordering documentation shows those criteria are met.

    • Breast GEP: newly diagnosed within 6 months OR currently on adjuvant hormonal therapy with plan to use result to guide extended endocrine therapy.
    • Thyroid: indeterminate FNA (Bethesda III/IV) and result will change surgical decision‑making.
    Note

    Screening tests handled under Preventive Care Services — verify benefit linkage

    Cancer screening tests that fall under preventive care (e.g., some CRC screening considerations) are handled separately under the Preventive Care Services policy; do not assume linkage of screening tests to this molecular testing benefit without checking preventive care policy.

    • Guardant Shield (blood‑based CRC screening) is FDA‑approved; positive results require diagnostic colonoscopy per standard of care.
    Step Therapy

    No explicit step therapy mandates — use tests after standard risk assessment

    No comprehensive step therapy sequencing mandates are specified in the policy excerpts; however, genomic assays should be used after standard risk assessment and when results would affect management rather than routinely ordered without documented clinical need.

    • ASCO/NCCN recommend selective use — document prior risk assessment and how test results will alter management.
    Documentation Required

    Document clinical decision impact when assays used to alter systemic therapy

    The evidence summaries describe how Recurrence Score and other genomic assays influenced chemotherapy decisions in trials and registries but do not create mandated step therapy sequences; document clinical reasoning when requesting coverage for tests intended to change systemic therapy.

    • Provide clinical factors (age, nodal status, RS when available) and treatment‑decision intent in authorization/medical record.
    Step Therapy

    Do not order molecular testing if surgery is already the preferred management

    When surgical treatment is clearly preferred (for example when thyroidectomy is indicated on clinical/imaging grounds), molecular testing is unnecessary; order testing only if surgical decision remains unclear after integrating clinical, imaging, and cytology data and document that rationale.

    • AAES: if thyroidectomy preferred clinically, molecular testing is unnecessary; use testing when decision remains unclear.
    Documentation Required

    Supply medical records to substantiate clinical criteria for review

    Provide relevant medical records when requesting review for molecular testing coverage; medical records may be required to substantiate that clinical criteria are met but supplying records does not guarantee coverage.

    • Include prior pathology, imaging, staging, treatment history, and clinician rationale with the authorization request.
    Documentation Required

    Records may be required to assess eligibility — documentation not a guarantee of coverage

    Medical records provided for prior authorization or appeal should document how the member meets the policy’s clinical criteria; reviewers may request additional records to assess medical necessity but documentation does not ensure approval.

    Documentation Required

    Provide documentation showing test purpose and that assay meets multigene definition

    Supporting documentation should demonstrate that the test is being used for diagnosis, prognosis, or treatment selection in a solid tumor and state whether the assay meets the policy’s multigene definition (generally ≥5 genes) or is a named assay described as proven.

    • If a multigene panel is claimed, include gene list or lab report showing gene count to confirm multigene definition.
    Documentation Required

    Document decision impact when using BCI (pre/post recommendations, patient preference)

    If using Breast Cancer Index (BCI) to support extended endocrine therapy decisions, document pre‑ and post‑test physician recommendations and patient preference questionnaires to demonstrate that test results affected management.

    • Registry data show physician EET recommendations changed after BCI testing; include clinician notes showing the change.
    Documentation Required

    Document Decipher results with clinical risk features

    When Decipher results are used to inform prostate cancer management, document the Decipher score and risk category alongside clinicopathologic features (e.g., CAPRA, Gleason grade, PSA) to support the interpretation and intended management change.

    • Include Decipher report, pathology, PSA, and treatment plan in the prior authorization submission.
    Documentation Required

    Document specimen type and testing method; obtain metastatic biopsy when feasible

    Document specimen source and testing method: obtain metastatic biopsy for histology and molecular evaluation when feasible; if biopsy is unsafe or unfeasible, document why and that plasma ctDNA was used as an alternative, including plans for tissue testing if required.

    • NCCN: metastatic biopsy recommended for molecular evaluation; plasma ctDNA an option if biopsy unsafe/unfeasible; note PSA undetectable caveat.
    Documentation Required

    Include tumor stage/T category and SLNB eligibility when testing for SLNB guidance

    Required clinical documentation for assays that influence SLNB decisions should include tumor T category/stage, assessment of SLNB eligibility, and the gene expression test result because studies link these variables to SLNB outcomes.

    • Provide pathologic T category, tumor thickness (for melanoma), clinical node status, and the GEP report when requesting authorization.
    Billing Rule

    Positive Shield test requires diagnostic colonoscopy follow‑up

    For Guardant Shield (Shield) screening, document that a positive blood‑based CRC screening result will be followed by diagnostic colonoscopy per standard of care; follow‑up colonoscopy is required after a positive Shield test.

    Denial Risk

    Denial risk: FDA‑cleared companion diagnostics or tests labeled unproven

    Denials are likely if the test is an FDA‑cleared/approved companion diagnostic (those tests are excluded from this policy) or if a test is explicitly categorized as unproven/not medically necessary in the policy.

    • Tests explicitly identified as unproven are considered not medically necessary and may be denied.
    Denial Risk

    Documentation may affect but does not guarantee coverage

    Supplying medical records and documentation may influence but will not guarantee coverage decisions; reviewers may still deny tests that do not meet the policy’s clinical criteria or evidence standards.

    Denial Risk

    Risk of denial if assay fails multigene definition or is not described

    Tests that do not meet the policy’s multigene definition (generally five or more genes) or that are not described/listed as proven in the policy may be at risk for denial; include gene counts or assay description to demonstrate policy alignment.

    • If a panel is <5 genes or lacks evidence of clinical utility, state rationale and supporting literature when requesting coverage.
    Denial Risk

    Insufficient evidence for other breast/DCIS GEPs — denial risk

    Assays for breast cancer or DCIS not explicitly supported in the policy (for example DCISionRT or other GEPs beyond the named breast assays) lack sufficient evidence and are at risk for coverage denial.

    Denial Risk

    ctDNA alone in non‑metastatic disease may be noncovered

    Using ctDNA alone in non‑metastatic contexts (in lieu of tissue diagnosis) risks noncoverage; the policy and guidelines state ctDNA should not replace tissue diagnosis except in advanced/metastatic disease and tissue insufficiency contexts.

    • If ctDNA is used because tissue is unobtainable, document reasons and plan for tissue confirmation if ctDNA is non‑informative.
    Denial Risk

    Insufficient evidence may trigger noncoverage for certain assays

    Tests with insufficient peer‑reviewed evidence (examples: MyProstateScore 2.0, OncoAssure, Confirm mdx) were judged to lack support for routine clinical implementation and may be denied; cite Hayes assessments when relevant.

    • Provide high‑quality published evidence if requesting coverage for these assays; lack thereof increases denial risk.
    Denial Risk

    Denial risk when tests replace recommended imaging or lack guideline validity

    Coverage risk increases if molecular testing is used as a replacement for guideline‑recommended imaging (e.g., using biomarkers instead of multiparametric MRI); document why standard methods are not feasible if requesting an alternative approach.

    • NCCN: biomarker testing is not recommended as a replacement for multiparametric MRI.
    Denial Risk

    Evidence insufficiency (low‑quality studies) may lead to denial

    Tests with low‑quality evidence or no demonstrated clinical utility (per technology assessments such as Hayes or when evidence is limited) are at risk for denial; supply robust outcome data to support coverage requests for such tests.

    • Hayes assessments cited as sources indicating low or very low quality evidence for some assays.
    Denial Risk

    Do not replace surgical/path staging with GEP outside trials — denial risk

    NCCN cautions that predictive GEP testing should not be used to replace surgical/pathological staging (e.g., to avoid SLN discussion); ordering such testing instead of recommended staging may trigger denial unless in a clinical trial.

    • Document trial enrollment if test is ordered in the context of an approved clinical study.
    Denial Risk

    Risk of denial when urine tests used outside studied lower‑risk populations

    Using urine molecular tests outside the populations studied (for example, replacing cystoscopy in higher‑risk surveillance or high‑risk microhematuria) risks denial; prior authorization should reference trial populations and guideline recommendations supporting use.

    • AUA: UBTMs may be offered to appropriately counseled intermediate‑risk patients who accept avoiding cystoscopy; do not substitute for guideline care in high‑risk patients.
    Denial Risk

    CUP tissue‑of‑origin GEPs have evidence insufficiency — denial risk absent actionable utility

    Molecular tests intended solely to infer tissue of origin in CUP or to identify primary site via GEP lack sufficient peer‑reviewed evidence and may be denied; CGP to guide therapy in unfavorable CUP requires documentation of actionable findings and intended targeted therapy.

    • CUPISCO showed benefit when actionable alterations were present; document actionable result plan if using CGP in CUP.

    Applicable Procedure and Test Codes

    Applicable procedure codes (sample group)mixed
    0005UOncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score.
    0011MOncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk
    0012MOncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma.
    0013MOncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes..., utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma.
    0016MOncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing FFPE tissue, algorithm reported as molecular subtype.
    0018UOncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as positive or negative for moderate to high risk of malignancy.
    0019UOncology, RNA, gene expression by whole transcriptome sequencing, FFPE or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents.
    0020MOncology (central nervous system), analysis of DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass.
    Applicable procedure codes (comprehensive group)mixed
    0026UOncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, FNA of thyroid nodule, algorithmic analysis categorical result.
    0036UExome (somatic mutations), paired FFPE tumor tissue and normal specimen, sequence analyses.
    0045UOncology (breast DCIS), mRNA, gene expression profiling by RT-PCR of 12 genes, FFPE tissue, algorithm reported as recurrence score.
    0047UOncology (prostate), mRNA, gene expression profiling by RT-PCR of 17 genes, FFPE tissue, algorithm reported as risk score.
    0048UOncology (solid organ), DNA, targeted sequencing of 468 cancer-associated genes, matched normal specimens, FFPE tissue, report of clinically significant mutation(s).
    0069UOncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, FFPE tissue, algorithm reported as an expression score.
    0089UOncology (melanoma), gene expression profiling by RT-qPCR, PRAME and LINC00518, superficial collection using adhesive patch(es).
    0090UOncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes, FFPE tissue, categorical result.
    0113UOncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, RNA amplification and fluorescence-based detection, algorithm reported as risk score.
    0153UOncology (breast), mRNA, gene expression profiling by NGS of 101 genes, FFPE tissue, algorithm reported as TNBC clinical subtype(s) with immune info.
    1–10 of 31
    1/4
    Applicable molecular oncology CPT/PLA and HCPCS codesmixed
    0478UOncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK1/2/3, ERBB2, and MET) in FFPE tissue
    0485UOncology (solid tumor), cell-free DNA and RNA by NGS, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived SNVs, indels, CNAs, fusions, MSI, and TMB
    0486UOncology (pan-solid tumor), NGS analysis of tumor methylation markers in cfDNA, algorithm reported as quantitative methylation correlate of tumor fraction
    0487UOncology (solid tumor), ctDNA targeted genomic sequence panel of 84 genes, sequence variants, copy number, rearrangements, MSI
    0496UOncology (colorectal), cfDNA, 8 genes for mutations, 7 genes for methylation, and 4 proteins by ELISA, blood; reported positive/negative for colorectal cancer or advanced adenoma risk
    0497UOncology (prostate), mRNA gene-expression profiling by RT-PCR of 6 genes in FFPE, risk score
    0498UOncology (colorectal), NGS for mutation detection in 43 genes and methylation pattern in 45 genes, blood and FFPE tissue
    0499UOncology (colorectal and lung), DNA from FFPE tissue, NGS of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, ...)
    0501UOncology (colorectal), blood, quantitative measurement of cfDNA
    0507UOncology (ovarian), DNA whole-genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not
    1–10 of 53
    1/6
    Covered CPT Codesmixed
    No codes listed
    Referenced commercial testsmixed
    Guardant ShieldcfDNA blood-based colorectal cancer screening test (commercial name referenced in evidence)
    Recency of breast cancer diagnosis for GEP testing
    Recency requirementNewly diagnosed within the last 6 months
    Node statusLymph node negative (including micrometastases ≤2 mm) or 1–3 positive ipsilateral axillary lymph nodes
    Metastatic statusNo distant metastases
    Receptor statusHormone receptor positive and HER2 receptor negative
    Therapy considerationAdjuvant chemotherapy must not be precluded by other factors (e.g., advanced age or significant comorbidities)
    Age range for Shield colorectal screening
    Primary age range45–75 years
    Extended age groupAged 76–85 years if never previously screened, healthy enough for treatment if CRC detected, and no comorbidities that significantly limit life expectancy
    Follow-up requirementIndividual agrees to undergo follow-up colonoscopy if Shield results are abnormal
    Gene limit for NSCLC panels
    Maximum gene countPanels that include no more than 50 genes are medically necessary for NSCLC
    Context noteNCCN notes many marketed NGS assays for NSCLC exceed 50 genes — policy limits Medicare Advantage statement to ≤50 genes
    Test typeApplies to multigene molecular profiling panels for non–small cell lung cancer
    Prostate cancer risk category criteria
    Very Low RiskPSA <10 ng/mL; grade group 1; <3 positive biopsy cores with ≤50% cancer in each core; T1c; PSA density <0.15 ng/mL/g
    Low RiskPSA <10 ng/mL; grade group 1; T1–T2a disease (does not qualify for very low risk)
    Favorable Intermediate RiskNo high/very high features; grade group 1–2; <50% positive biopsy cores; and one intermediate risk factor (T2b–T2c or PSA 10–20 ng/mL or grade group 2–3)
    Unfavorable Intermediate RiskNo high/very high features and one or more of: grade group 3, ≥50% positive cores, or two–three intermediate risk factors (T2b–T2c, grade group 2–3, PSA 10–20 ng/mL)
    High RiskNot very high but has ≥1 high-risk feature (T3–cT4, grade group 4–5, or PSA >20 ng/mL)
    Multigene panel gene count threshold
    Multigene panel definitionFor this policy, multigene analysis generally refers to a gene panel containing five or more genes
    ExceptionsSome exceptions may apply and are noted specifically in policy text or code lists
    Operational useUsed to distinguish single–gene tests from panels and as basis for coverage/denial considerations
    PSA range commonly evaluated for ExoDx
    Common PSA range2–10 ng/mL
    Intended useRange commonly studied for ExoDx Prostate to aid initial or repeat biopsy decision-making
    Evidence noteProspective utility trial (Tutrone et al.) enrolled participants within this PSA range; evidence quality judged low to moderate by Hayes
    EpiScore positive threshold
    Positive thresholdEpiScore ≥ 60 (positive)
    Score useEpiScore generated by PCR-based urine methylation assays (Bladder EpiCheck) to detect NMIBC recurrence
    Alternate cutoffHigher cutoffs (e.g., ≥80) reported in studies and associated with greater recurrence risk
    TMB threshold examples
    Median TMB exampleMedian TMB reported 3.75 mutations per megabase
    High TMB prevalence example11.6% of specimens had TMB ≥ 16 mutations per megabase
    ContextReported in CGP/CUP cohorts assessing eligibility for targeted or immunotherapy approaches

    Not Covered / Unproven Tests

    All molecular oncology tests for solid tumors not specifically listed as proven/covered in the policy are considered unproven and not medically necessary due to insufficient evidence of clinical efficacy.

    The policy explicitly identifies a set of tests labeled “Unproven Molecular Tests”. Examples listed as not covered include many named assays across tumor types (see the policy’s unproven tests list), such as multicancer detection assays, specific urine or plasma biomarker tests, and certain GEPs that lack sufficient validation.

    Predictive evidence is insufficient to support some assays for predictive use in node-positive disease (for example, Prosigna and EndoPredict predictive data are limited in node-positive populations). These insufficiencies may result in noncoverage for the predictive indication absent stronger, prospective evidence.

    Hayes-based evaluations cited in the policy indicate that Oncotype DX is not supported for N2 disease (four to nine positive lymph nodes) because available evidence does not sufficiently establish benefit for this population.

    Hayes assessments found limited prospective utility data for EndoPredict and identified gaps in evidence for BCI’s predictive claims, which may justify classifying certain uses of these assays as noncovered where utility is unproven.

    Other gene expression profiling assays for breast cancer or DCIS beyond those described in the coverage sections (for example, DCISionRT and Oncotype DX DCIS Score) lack sufficient evidence of clinical utility and may be excluded from coverage.

    Hayes concluded that the evidence supporting DCISionRT is insufficient and that the Oncotype DX DCIS evidence body is low quality; these findings support noncoverage for routine clinical application for DCIS management pending stronger evidence.

    Use of ctDNA in place of tissue diagnosis in non-advanced or non-metastatic disease is not recommended and may be considered noncovered when used as a substitute for tissue-based diagnosis rather than as an adjunct or when tissue is unobtainable.

    For prostate-related biomarkers, tests that lack peer-reviewed evidence of clinical utility—such as MyProstateScore 2.0, OncoAssure, Confirm mdx—are not supported for routine clinical implementation and may be considered noncovered for those indications.

    Select mdx was judged by Hayes to have a very low-quality evidence base and inadequate data to conclude effectiveness for predicting clinically significant prostate cancer; such findings support noncoverage for routine use pending stronger evidence.

    Earlier assessments for thyroid panels (ThyGeNEXT/ThyraMIR) were considered inadequate to reclassify indeterminate nodules conclusively in some contexts; as a result, certain uses may be noncovered where evidence is insufficient to support management changes.

    Routine molecular profiling to stratify progression risk for low-risk papillary thyroid carcinoma under active surveillance is not supported by the evidence and is not recommended for guiding enrollment or routine management decisions.

    The Hayes assessment found the evidence for MyPath Melanoma insufficient to support diagnostic adjunct use; the test is therefore not supported for routine clinical use to change management.

    Professional guideline groups and technology assessments discourage routine prognostic GEP testing for cutaneous melanoma to guide sentinel lymph node decisions or routine management outside of clinical trials; such routine use is not supported and may be noncovered.

    Tests lacking demonstrated clinical utility or with very low-quality supporting evidence (per Hayes and other assessments) when used to change management beyond investigational or guideline-supported contexts may be excluded from coverage.

    Molecular tests intended solely to infer tissue of origin for CUP (for example, CancerTYPE ID and similar GEP assays) have insufficient evidence of clinical effectiveness and are noted as likely noncovered absent convincing outcome data.

    Background and Scope

    Molecular oncology testing encompasses a wide range of technologies used to evaluate DNA, RNA, methylation, and other tumor-derived analytes. The policy covers molecular profiling intended to inform diagnosis, prognosis, and treatment selection across solid tumors, but applies only to tests that are not FDA-cleared/approved as companion diagnostics.

    Clinical evidence summaries and scope statements in the policy underscore that several gene expression profiling assays (Oncotype DX, Prosigna, EndoPredict, MammaPrint, BCI) have prognostic value in early HR-positive/HER2-negative breast cancer, but predictive evidence for chemotherapy benefit is strongest for Oncotype DX and remains limited for other assays.

    Definitions

    Companion diagnostic — FDA-cleared or approved test excluded from this policy
    DefinitionA test that is FDA-cleared or approved to inform use of a specific therapeutic
    Policy scope implicationTests with FDA companion diagnostic status are excluded from this policy's scope
    Operational noteCoverage determinations for FDA-cleared/approved companion diagnostics follow separate companion diagnostic policy
    Comprehensive Genomic Profiling definition
    DefinitionComprehensive Genomic Profiling (CGP): broad NGS-based tumor sequencing to detect multiple alteration classes (SNVs, indels, CNAs, fusions), TMB, and MSI to identify actionable biomarkers
    Specimen typesPerformed on tissue or plasma (ctDNA) when tissue unavailable; may include paired normal analysis
    Typical useUsed to identify candidate targeted or immunotherapy options and for enrollment in trials (e.g., CUPISCO)
    Gene Expression Profiling definition
    DefinitionGene Expression Profiling (GEP): laboratory tests that analyze tumor mRNA patterns to determine gene activity and generate prognostic or predictive classifiers or scores
    ApplicationsUsed for prognosis, prediction of therapy benefit, tissue‑of‑origin classification, or SLNB decision support depending on assay
    Example assaysOncotype DX, MammaPrint, Prosigna, EndoPredict, Breast Cancer Index, DecisionDx-UM, 31-GEP
    Liquid Biopsy definition
    DefinitionLiquid biopsy: testing of bodily fluid (commonly plasma) to detect circulating tumor cells, cell-free tumor DNA (ctDNA), RNA, or other tumor-derived molecules for detection, profiling, or monitoring
    Use casesIdentify resistance mechanisms, perform CGP when tissue insufficient or patient unfit for biopsy, or for MRD assessment
    Policy cautionctDNA should not replace tissue diagnosis in non‑metastatic settings and should be followed by tissue testing if no driver is found
    Whole-Exome & Whole-Genome Sequencing definitions
    Whole-Exome Sequencing (WES)Analyzes all exons (protein‑coding regions) of the genome in a sample
    Whole-Genome Sequencing (WGS)Determines the sequence of the entire genome including coding and noncoding regions
    Use and scopeUsed for broad discovery or research and may identify germline or somatic alterations across the genome
    Multigene analysis definition (generally ≥ 5 genes)
    DefinitionMultigene analysis: gene panels generally containing five or more genes (policy operational definition)
    ImplicationPanels with fewer genes may not meet multigene definition and could be subject to different review or denial
    ExceptionsPolicy notes exceptions may apply and specific tests are described individually
    Recurrence Score (RS) — Oncotype DX description
    Recurrence Score (RS) / Oncotype DX21‑gene expression–based Recurrence Score used to stratify distant recurrence risk and guide adjuvant chemotherapy decisions (preferred by NCCN)
    Clinical contextValidated in node‑negative and selected node‑positive (1–3 nodes) patients; strong predictive evidence for chemotherapy benefit compared with other GEAs
    Assay nameOncotype DX Breast Recurrence Score
    ROR (Prosigna) — PAM50 description
    DefinitionProsigna (PAM50) provides a 46‑gene Risk of Recurrence (ROR) score and intrinsic subtype (luminal A/B) for prognostication, particularly postmenopausal ER+ early breast cancer
    Clinical noteIdentifies very low long‑term local recurrence subgroups after breast‑conserving surgery and endocrine therapy; predictive value for radiation benefit not demonstrated
    Assay nameProsigna Breast Cancer Assay (PAM50 ROR)
    MP-LR / MP-HR / EPclin definitions (MammaPrint/EndoPredict)
    MP‑LR / MP‑HR / EPclinMammaPrint (70‑gene) classifies low‑risk (MP‑LR) vs high‑risk (MP‑HR); EndoPredict EPclin integrates molecular score with clinicopathologic features
    Clinical contextMammaPrint has trial data (MINDACT, I‑SPY2) for neoadjuvant/adaptive settings; EPclin stratifies relapse risk and may predict NET response
    Assay namesMammaPrint (70‑gene), EndoPredict (EPclin)
    EPclin definition
    EPclinEndoPredict combined molecular and clinicopathologic score that stratifies risk (EPclin low‑risk vs high‑risk) and is independently prognostic for DFS and DMFS
    EvidenceProspective and retrospective cohorts show EPclin prognostic performance though prospective utility across diverse populations is limited
    Use caseMay inform neoadjuvant endocrine therapy response prediction in select studies
    BCI H/I definition
    BCI H/IBreast Cancer Index HOXB13:IL17BR (H/I) ratio component used to predict likelihood of benefit from endocrine therapies and late distant recurrence risk
    Clinical signalBCI has predictive signals for extended endocrine therapy benefit in some trials and registries, though evidence is variable
    ApplicationUsed to inform decisions about extended adjuvant endocrine therapy
    ctDNA definition and prognostic note
    ctDNA definitionCirculating tumor DNA (ctDNA): tumor-derived cell‑free DNA detectable in plasma; baseline detection is associated with worse survival in metastatic settings
    Prognostic noteSystematic reviews show baseline ctDNA alterations associated with poorer OS and PFS (pooled HR ~1.40)
    Use cautionctDNA is prognostic but not yet routinely an actionable sole determinant for therapy selection in many contexts
    DCISionRT definition
    DCISionRTMolecular assay used in ductal carcinoma in situ (DCIS) to prognosticate local recurrence and potentially predict benefit from radiotherapy
    EvidenceStudies and meta-analyses exist but overall clinical utility and outcome‑improving evidence remain limited
    ComparisonRelated DCIS assays include Oncotype DX DCIS Score; evidence quality generally low to moderate
    Oncotype DX Breast DCIS Score definition
    Oncotype DX Breast DCIS ScoreA multigene expression assay that provides a DCIS recurrence score intended to estimate 10‑year recurrence risk and assist treatment decisions
    Evidence limitationsHayes assessment concluded low‑quality evidence and uncertain impact of score‑based decisions on outcomes
    Use contextMay inform RT and surgical decisions in DCIS alongside clinical factors but lacks robust outcome data
    Broad NGS panel definition
    Broad NGS panelNext‑generation sequencing assays profiling many genes (often >50) to identify actionable genomic alterations, TMB, and MSI for treatment selection
    Typical applicationRecommended/used in NSCLC and other advanced solid tumors to identify targeted therapy options
    Policy notePolicy distinguishes panels ≤50 genes (allowed for certain indications) vs broader panels; NCCN acknowledges panels >50 genes are common
    ctDNA definition (plasma cfDNA for profiling)
    ctDNA (plasma cfDNA)Cell‑free tumor DNA in plasma used for molecular profiling when tissue is unavailable or to assess resistance mechanisms; may be used in parallel with tissue testing
    Use constraintsNot recommended in lieu of tissue diagnosis in non‑metastatic disease; follow with tissue testing if ctDNA negative for driver
    ApplicationsCGP via plasma for advanced/metastatic disease and to expedite genotyping when tissue limited
    Genomic Classifiers (GCs) definition — Decipher/GPS/Prolaris
    Genomic Classifiers (GCs)Tissue‑based multigene expression classifiers (e.g., Decipher, Genomic Prostate Score/GPS, Prolaris) that generate scores to predict recurrence, metastasis, or adverse pathology
    Use casesPrognostic risk stratification in localized prostate cancer and to inform active surveillance vs definitive therapy or adjuvant decisions
    EvidenceEvidence varies by test; Decipher has substantial prognostic data in intermediate‑risk and post‑RP settings
    Decipher genomic classifier definition
    Decipher GCA 22‑gene expression classifier applied to prostate biopsy or prostatectomy tissue providing a continuous risk score and categorical risk used for prognostication
    Clinical utilityEvidence supports prognostic association with progression, metastasis, and mortality; recommended by NCCN as an option for post‑RP adjuvant decision discussions
    Typical settingsIntermediate‑risk disease and post‑prostatectomy risk stratification
    ExoDx Prostate Test definition
    ExoDx Prostate TestA urine exosome–based biomarker assay to assess risk of high‑grade prostate cancer and inform biopsy decisions (studied mainly in PSA 2–10 ng/mL)
    EvidenceProspective randomized utility trial (Tutrone et al.) showed influence on biopsy decisions; systematic reviews report improved accuracy vs PSA alone
    LimitationsOverall clinical utility evidence limited and Hayes assessment rated evidence low‑quality in some updates
    ctDNA definition (alternate chunks) — guidance for metastatic biopsy substitution
    ctDNA biopsy substitution guidanceWhen metastatic biopsy is unsafe or unfeasible, plasma ctDNA is an option for histological/molecular evaluation; collect tissue if ctDNA is negative for driver
    DocumentationDocument rationale for using plasma ctDNA (e.g., unfit for biopsy or insufficient tissue) and plan for follow‑up tissue testing if needed
    LimitationCollection of plasma ctDNA not recommended when PSA is undetectable in prostate cancer contexts
    Decipher GC (duplicate) definition
    Decipher GC (duplicate)22‑gene genomic classifier used for advanced risk stratification post‑prostatectomy and in intermediate‑ to high‑risk prostate cancer
    Clinical applicationMay inform adjuvant therapy discussions and post‑RP management when adverse features present
    Evidence sourcesAncillary analyses of randomized trials and large registry cohorts support prognostic associations
    GSC (Afirma) definition
    Genomic Sequencing Classifier (GSC) — AfirmaA genomic sequencing classifier intended to identify benign thyroid nodules among indeterminate FNA results with high sensitivity and NPV
    Clinical noteHayes assessment supports high sensitivity/NPV but specificity and PPV vary; may help avoid unnecessary surgery
    ExamplesAfirma GSC, Afirma Xpression Atlas (XA)
    ThyroSeq V3 definition and evidence note
    ThyroSeq V3An NGS‑based genomic classifier aimed at predicting malignancy probability in Bethesda III/IV thyroid nodules; shows high sensitivity/NPV but Hayes found overall evidence low‑quality with limited outcome data
    Use contextMay help rule out malignancy in indeterminate nodules when results will change management
    Evidence limitationLack of reference standard and insufficient follow‑up for negatives in some studies
    31-GEP / CP-GEP / Merlin definitions — melanoma SLNB prediction tests
    31‑GEP / CP‑GEP / MerlinGEP tests to predict sentinel lymph node positivity risk in cutaneous melanoma to inform SLNB decisions (31‑GEP = 31‑gene; CP‑GEP = clinicopathologic + GEP/Merlin)
    Performance notes31‑GEP studies reported false omission rates meeting NCCN thresholds in some analyses; CP‑GEP results vary and sometimes fall short of NCCN standards
    Use cautionGuidelines generally discourage routine replacement of staging with GEP; tests should be used when results will affect management
    31-GEP / DecisionDx-Melanoma definition
    DecisionDx‑Melanoma (31‑GEP)A 31‑gene expression profile test used to stratify cutaneous melanoma recurrence/metastasis risk and influence SLNB decision‑making; reported to reduce SLNB rates in some prospective studies
    EvidenceProspective studies (DECIDE, Yamamoto) show impact on clinician decisions and reductions in SLNBs for class 1A; outcome data still accruing
    LimitationsStudies often manufacturer‑funded and require further high‑quality prospective validation
    CP-GEP (Merlin) definition
    CP‑GEP (Merlin)Clinicopathologic + gene‑expression profile combining tumor and clinical features to predict sentinel lymph node metastasis risk in melanoma
    Study resultsProspective multicenter study (Hieken et al.) reported NPV 92.9% with 7.1% SLN positivity among low‑risk, indicating potential utility but not definitive clinical utility
    Evidence limitationsHayes found limited clinical validity and no clinical utility studies in some assessments
    Pigmented Lesion Assay (PLA / DermTech) definition
    Pigmented Lesion Assay (PLA / DermTech)Tape‑stripping adhesive patch test detecting RNA markers (e.g., LINC00518, PRAME, TERT) for noninvasive assessment of suspicious pigmented lesions
    Diagnostic accuracySystematic reviews report sensitivity and specificity ranges; clinical utility to reduce unnecessary biopsies remains uncertain
    Real‑world issuesAssay failures and discordance with histopathology reported in some series; more robust studies needed
    DecisionDx-UM definition
    DecisionDx‑UMA 15‑gene expression profile test for uveal melanoma that classifies tumors as class 1A/1B or class 2 and, when combined with PRAME expression, refines metastatic risk stratification
    Prognostic performanceProspective multicenter cohort (Harbour et al.) shows marked separation in 5‑year MFS/MSS across classes and PRAME status
    Clinical useUsed to guide surveillance intensity and trial stratification when biopsy is performed
    DecisionDx-UM 15-GEP class definition
    15‑GEP outputDecisionDx‑UM yields class 1A/1B (lower risk) or class 2 (higher risk) prognostic categories
    Integrated classifierCombining PRAME status with class improves risk discrimination (four-group classifier) for metastatic‑free survival
    Intended usePrognostication of primary localized uveal melanoma to inform surveillance and trial eligibility
    PCR-based urine methylation assay (EpiScore) definition
    EpiScore assayPCR‑based urine methylation assay generating an EpiScore used by Bladder EpiCheck
    Positive thresholdEpiScore ≥ 60 considered positive in studies; higher cutoffs (e.g., ≥80) associated with greater recurrence risk
    Clinical performanceMeta‑analysis reports pooled sensitivity ~69% and specificity ~87%; high‑grade NPV reported as high (~95%) in cohort studies
    EpiScore definition and positive threshold context
    EpiScore — assay contextEpiScore positive defined as ≥ 60 in pooled studies; used to triage surveillance and predict high‑grade recurrence
    Stratified cutoffsStudies report increasing PPV with higher EpiScore ranges (e.g., ≥80 strongly associated with recurrence)
    Specimen typesVoided urine or bladder washing specimens used in studies; reporting of numeric EpiScore and cutoff recommended for documentation
    Cxbladder Triage definition
    Cxbladder TriageUrinary genomic test intended to triage patients with microhematuria to reduce unnecessary cystoscopy; in RCT, demonstrated sensitivity 90% and NPV 99% in lower‑risk participants
    Intended useAdjunct to standard evaluation in lower‑risk microhematuria to avoid cystoscopy when appropriate
    LimitationsApplicability limited to trial‑defined lower‑risk populations; not recommended to replace cystoscopy in higher‑risk patients
    Decipher Bladder genomic classifier definition
    Decipher Bladder GCTranscriptome‑based genomic classifier that assigns luminal vs nonluminal subtypes and predicts upstaging risk and differential benefit from neoadjuvant chemotherapy
    Clinical findingsRetrospective studies link nonluminal tumors with higher upstaging and greater benefit from NCT; prospective validation pending
    SpecimenFFPE tumor tissue from transurethral resection or cystectomy specimens used in studies
    DecisionDx-SCC definition
    DecisionDx‑SCC (40‑GEP)A 40‑gene expression profiling test that classifies cutaneous squamous cell carcinoma into risk categories (class 1, 2A, 2B) for metastasis risk to inform adjuvant radiotherapy decisions
    Intended usePrognostic stratification to identify high‑risk patients who may benefit from ART
    Evidence statusRetrospective validations and consensus guidelines exist but prospective utility data are limited; potential conflicts of interest noted in some studies
    CGP definition (broad NGS for TMB/MSI/alterations)
    CGP (duplicate) — definitionBroad NGS‑based tumor sequencing to identify genomic alterations, TMB, MSI, and other biomarkers used to guide targeted or immunotherapy approaches
    ApplicationUsed in CUP and metastatic settings to identify actionable alterations; trials (CUPISCO) showed improved PFS with MGT in selected patients
    Specimen optionsTissue preferred; plasma ctDNA acceptable when tissue unavailable, with caveats
    GEP definition (RNA-based tissue-of-origin or prognostic assays)
    GEP (duplicate) — definitionAssays measuring tumor RNA/transcriptional patterns to predict tissue of origin or prognostic classes (e.g., DecisionDx‑SCC, CancerTYPE ID); used for prognosis, tissue‑of‑origin inference, or therapeutic guidance depending on test
    LimitationsClinical utility for tissue‑of‑origin GEP in CUP is limited; DNA sequencing may offer higher diagnostic yield in unresolved CUPs
    ExamplesDecisionDx‑SCC, 31‑GEP, CancerTYPE ID, DecisionDx‑UM

    Additional Provider Actionables and Documentation Requirements

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Revision History

    2026-08-01policy_effectiveLatest

    Policy effective date updated to August 1, 2026; scope clarifies applicability to UnitedHealthcare Commercial and Individual Exchange plans and excludes FDA-cleared/approved companion diagnostics from this policy's scope.

    2026-08-01coverage_revision

    Added or clarified proven/medically necessary indications (breast GEP assays, Shield blood-based CRC screening, NSCLC panels ≤50 genes, prostate genomic tests, anaplastic thyroid CGP, indeterminate thyroid nodule testing, DecisionDx-UM for uveal melanoma) and listed multiple tests classified as unproven/not medically necessary.

    2026-08-01coding_update

    Applicable CPT/HCPCS code list updated: added codes 0285U, 0405U, 0534U, 0560U, 0561U, and S3854 and removed codes 0022U, 0037U, 0211U, 0239U, 0242U, 0523U, and 0592U.

    2026-08-01operational_update

    Medical records documentation requirements expanded to specify provider specialty, primary cancer diagnosis/pathology, prior test results and how test results will affect clinical management.